Tag Archives | biotech portfolios and ETFs

Biotech Stocks Are Apparently Immune to Risks of the Day: New Highs Again …Update 2

3:55 p FEDspeak confuses markets with S&P down 1.25% Too much money around too little yield=deflation concerns. Energy takes a big hit again down 4%. Biotechs off 2% and more. ——— Update 1/28 Technology outperforming biotech in mid-day trading AAPL and semiconductor stocks are leading the NASDAQ up today. Speculators in mid-cap biotech stocks are […]

Continue Reading 0

Rayno Life Science Stocks: Stealth Rally- CLVS, GILD, PCYC.. Update-1

1/27 Sell-Off Likely Today –Durable Goods Decreased 3.4% In December Green Screen In Biotech Despite Flat Market- Mid-Day Trading 12:45 p 1/26 Most Rayno Life Science stocks were up today in a mixed market where energy is the leading sector. XBI New High at 204.21 FBT up 1.5% to $111>New high at 111.38 XLV up […]

Continue Reading 0

MO Players Take Profits Again in Biotech-Risk Off: AGIO, BLUE, JUNO, PBYI, KITE, ZIOP

NASDAQ at 4667  up 0.27%     XBI at $194.4 down 2.88% Clinical Stage Immuno-oncology Stocks Hit Hard Again Momentum traders took money off the table for the second time in three days. Most large cap biopharmaceutical stocks were in the red but down less than 1 % except Alexion (ALXN) down 2%.The Rayno Mid-Cap […]

Continue Reading 0

JPMorgan Conference Notes #2: Biotech Stocks Surge to New Highs Then Sell Off on Energy/Materials Weakness

FBT up 2.4% to $108 then drifts back to 107; NASDAQ flat 4661 DOW bounced around in 425 point range. Mixed market among biotech stocks after NASDAQ  and S&P sell off; momentum eases. Mid-cap immuno-oncology stocks : down AGIO, BLUE, EPZM, SGEN.; up CLVS, INCY, MDVN. Rayno Life Science Movers: Pharmacyclics (PCYC) up 16% to […]

Continue Reading

2015 Biotech Stock Preview: Rhythms of the “PermaBull”

2015: Another Good Year Unless “Something Happens” Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as there were  two major corrections in April 2014 after the Q1 “bio-bubble” […]

Continue Reading